Practical approach to diagnosis and treatment of ocular allergy: A 1-year systematic review

Current Opinion in Allergy and Clinical Immunology

Volumn 7, Issue 5, 2007, Pages 446-449

  Bonini, Sergio ^a,c   Gramiccioni, Claudia ^b   Bonini, Matteo ^b   Bresciani, Megon ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b CNR   (Italy)

^c NONE   (Italy)

Author keywords

Allergic conjunctivitis; Antihistamines; Ocular allergy; Sublingual immunotherapy; Vernal keratoconjunctivitis

Indexed keywords

ANTIHISTAMINIC AGENT; CYCLOSPORIN A; EPINASTINE; KETOTIFEN; LEVOCABASTINE; LEVOCETIRIZINE; MITOMYCIN C; OLOPATADINE; OMALIZUMAB; TACROLIMUS;

ALLERGIC CONJUNCTIVITIS; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; EYE ALLERGY; HUMAN; IMMUNOTHERAPY; LOW DRUG DOSE; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT INDICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VERNAL CONJUNCTIVITIS;

ADMINISTRATION, SUBLINGUAL; ANTI-ALLERGIC AGENTS; ANTIBODIES, MONOCLONAL; CONJUNCTIVITIS, ALLERGIC; HISTAMINE H1 ANTAGONISTS; HUMANS; IMMUNOTHERAPY; KERATOCONJUNCTIVITIS;

EID: 34548680274     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e3282ef868b     Document Type: Review

References (29)

1. Schultz BL. Pharmacology of ocular allergy. Curr Opin Allergy Clin Immunol 2006; 6:383-389. This review gives pharmacological options for ocular allergy classified according to the target. Outcome measures are also discussed.
2. Bielory L. Differential diagnoses of conjunctivitis for clinical allergist-immunologists. Ann Allergy Asthma Immunol 2007; 98:105-114. This systematic review discusses clinical phenotypes of ocular allergy and their differential diagnosis.
3. Bielory L. Vasomotor (perennial chronic) conjunctivitis. Curr Opin Allergy Clin Immunol 2006; 6:355-360. This is an interesting review article on non IgE-mediated noninfectious conjunctivitis. Mechanisms and problems relating to the definition and classification of these forms of infection are discussed.
4. Eiseman AS. The ocular manifestations of atopic dermatitis and rosacea. Curr Allergy Asthma Rep 2006; 6:292-298.
5. Siddique M, Manzouri B, Flynn TH, Ono SJ. Allergy and contact lenses. Chem Immunol Allergy 2007; 92:166-175.
6. Wakefield D, McCluskey PJ. Vernal keratoconjunctivitis. Med J Aust 2006; 185:523.
7. Abelson MB, Granet D. Ocular allergy in pediatric practice. Curr Allergy Asthma Rep 2006; 6:306-311. Review of special interest for pediatric allergists and ophthalmologists.
8. Drugs for some common eye disorders. Treat Guidel Med Lett 2007; 5:1-8.
9. Friedlaender MH. Epinastine in the management of ocular allergic disease. Int Ophthalmol Clin 2006; 46:85-86.
10. Trattler WB, Luchs J, Majmudar P. Elestat (epinastine HCl ophthalmic solution 0.05%) as a therapeutic for allergic conjunctivitis. Int Ophthalmol Clin 2006; 46:87-99.
11. Bielory L. Ocular toxicity of systemic asthma and allergy treatments. Curr Allergy Asthma Rep 2006; 6:299-305. A nice review of the potential ocular side effects of medications used in the treatment of allergy and asthma, including corticosteroids (glaucoma and cataracts) and oral antihistamines (dry eye).
12. Pasquali M, Baiardini I, Rogkakou A, et al. Levocetirizine in persistent allergic rhinitis and asthma: effects on symptoms, quality of life and inflammatory parameters. Clin Exp Allergy 2006; 36:1161-1167.
13. Dake Y, Enomoto T, Cheng L, et al. Effect of antihistamine eye drops on the conjunctival provocation test with Japanese cedar pollen allergen. Allergol Int 2006; 55:373-378.
14. Finegold I, Granet DB, D'Arienzo PA, Epstein AB. Efficacy and response with olopatadine versus epinastine in ocular allergic symptoms: a post hoc analysis of data from a conjunctival allergen challenge study. Clin Ther 2006; 28: 1630-1638.
15. Takamura E, Nomura K, Fujishima H, et al. Efficacy of levocabastine hydrochloride ophthalmic suspension in the conjunctival allergen challenge test in Japanese subjects with seasonal allergic conjunctivitis. Allergol Int 2006; 55:157-165.
16. Okubo K, Ogino S, Nagakura T, Ishikawa T. Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Allergol Int 2006; 55:379-386. This paper reports on a randomized, placebo-controlled, double-masked study of 100 patients with seasonal allergic conjunctivitis. It is of interest because it discusses the efficacy and safety of omalizumab in relation to allergic symptoms not included as the main indication for the drug.
17. Kilic A, Gurler B. Topical 2% cyclosporine A in preservative-free artificial tears for the treatment of vernal keratoconjunctivitis. Can J Ophthalmol 2006; 41:693-698.
18. Jain AK, Sukhija J. Low dose mitomycin-C in severe vernal keratoconjunctivitis: a randomised prospective double blind study. Indian J Ophthalmol 2006; 54:111-116.
19. Cheng AC, Yuen K, Chan W. Topical tacrolimus ointment for treatment of refractory anterior segment inflammatory disorders. Cornea 2006; 25:634; author reply 634.
20. Rodriguez F, Boquete M, Ibanez MD, et al. Once daily sublingual immunotherapy without updosing: a new treatment schedule. Int Arch Allergy Immunol 2006; 140:321-326.
21. Worm M. Efficacy and tolerability of high dose sublingual immunotherapy in patients with rhinoconjunctivitis. Allerg Immunol (Paris) 2006; 38:355-360.
22. Vervloet D, Birnbaum J, Laurent P, et al. Safety and efficacy of Juniperus ashei sublingual-swallow ultra-rush pollen immunotherapy in cypress rhinoconjunctivitis: a double-blind, placebo-controlled study. Int Arch Allergy Immunol 2007; 142:239-246.
23. Palma-Carlos AG, Santos AS, Branco-Ferreira M, et al. Clinical efficacy and safety of preseasonal sublingual immunotherapy with grass pollen carbamylated allergoid in rhinitic patients: a double-blind, placebo-controlled study. Allergol Immunopathol (Madr) 2006; 34:194-198.
24. Rak S, Yang WH, Pedersen MR, Durham SR. Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: a double-blind, randomised study. Qual Life Res 2007; 16:191-201.
25. Valovirta E, Jacobsen L, Ljorring C, et al. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy 2006; 61:1177-1183. Randomized, placebo-controlled study of 88 children with two different schedules of sublingual immnunotherapy.
26. Bordignon V, Burastero SE. Multiple daily administrations of low-dose sublingual immunotherapy in allergic rhinoconjunctivitis. Ann Allergy Asthma Immunol 2006; 97:158-163.
27. Dahl R, Kapp A, Colombo G, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 118:434-440. Rigorous randomized, double-masked, placebo-controlled, parallel group study of sublingual immnuotherapy in 634 patients recruited in 51 centres from eight countries.
28. Passalacqua G, Canonica GW. Sublingual immunotherapy: update 2006. Curr Opin Allergy Clin Immunol 2006; 6:449-454. A valuable update of the efficacy of sublingual immunotherapy, with special reference to data showing a preventive effect on new sensitizations and to postmarketing surveys on safety.
29. Walker S, Monteil M, Phelon K, et al. Anti-IgE for chronic asthma in adults and children. Cochrane Library 2005; (3):1-61.